SpyGlass Pharma Statistics
Total Valuation
SpyGlass Pharma has a market cap or net worth of $684.05 million. The enterprise value is $434.65 million.
| Market Cap | 684.05M |
| Enterprise Value | 434.65M |
Important Dates
The next estimated earnings date is Monday, August 10, 2026, before market open.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SpyGlass Pharma has 33.43 million shares outstanding.
| Current Share Class | 33.43M |
| Shares Outstanding | 33.43M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +807.79% |
| Owned by Insiders (%) | 4.28% |
| Owned by Institutions (%) | 16.06% |
| Float | 6.48M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.73 |
| P/TBV Ratio | 2.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 38.00, with a Debt / Equity ratio of 0.01.
| Current Ratio | 38.00 |
| Quick Ratio | 37.75 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -19.64% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$659,765 |
| Employee Count | 68 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 20.88 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 52.78 |
| Average Volume (20 Days) | 169,066 |
Short Selling Information
The latest short interest is 1.01 million, so 3.03% of the outstanding shares have been sold short.
| Short Interest | 1.01M |
| Short Previous Month | 1.14M |
| Short % of Shares Out | 3.03% |
| Short % of Float | 15.61% |
| Short Ratio (days to cover) | 15.70 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -49.44M |
| Pretax Income | -44.86M |
| Net Income | -44.86M |
| EBITDA | -48.63M |
| EBIT | -49.44M |
| Earnings Per Share (EPS) | -$6.75 |
Balance Sheet
The company has $251.00 million in cash and $1.61 million in debt, with a net cash position of $249.40 million or $7.46 per share.
| Cash & Cash Equivalents | 251.00M |
| Total Debt | 1.61M |
| Net Cash | 249.40M |
| Net Cash Per Share | $7.46 |
| Equity (Book Value) | 250.11M |
| Book Value Per Share | 7.48 |
| Working Capital | 246.70M |
Cash Flow
In the last 12 months, operating cash flow was -$38.04 million and capital expenditures -$1.30 million, giving a free cash flow of -$39.35 million.
| Operating Cash Flow | -38.04M |
| Capital Expenditures | -1.30M |
| Depreciation & Amortization | 806,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -39.35M |
| FCF Per Share | -$1.18 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SpyGlass Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -6.56% |
| FCF Yield | -5.75% |
Analyst Forecast
The average price target for SpyGlass Pharma is $45.00, which is 119.94% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $45.00 |
| Price Target Difference | 119.94% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |